Drug shortages in the US have always been a predominant issue. Since the early 2000s, the proportion of injectable drug shortages has rarely fallen under 40%. Supply chain resiliency has been tested quite severely by the COVID-19 pandemic. Moreover, a resilient supply chain is a must to handle the ongoing drug and device shortage across the world, which has deteriorated rapidly since 2020. As such, many nations worldwide are taking initiatives to establish more robust supply chains to avoid similar situations.